TruScreen Limited has been granted Federal Drug Administration (FDA) approval to market its device in Thailand.
The potential Thai market for cervical cancer screening is estimated at NZ$50 million per annum.
TruScreen’s real time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissue to identify precancerous change, or cervical intraepithelial neoplasia (CIN).
TruScreen’s CEO Martin Dillon said “the Thai market is strategically significant for the company’s growth plans in the broader South East Asian Region and augments its existing distribution channels in the Philippines, Vietnam and Indonesia.” TruScreen intends to market its product in the broader ASEAN region immediately.
The total potential ASEAN cervical cancer screening market, with approximately 150 million women of screening age, is worth an estimated NZ$430 million per annum.
TruScreen has distribution contracts in 11 international markets, including China, Latin America, Central Asia, Russia, the Middle East and Eastern Europe.